Ozempic Butt: What Large Weight Loss Changes in the Buttocks

“Ozempic butt” is not a diagnosis, and there is no evidence the drug does anything to the buttocks in particular. It is what large weight loss does to a region built from fat, muscle and skin. The fat shrinks. Some gluteal muscle goes with it. Skin stretched for years does not fully pull back. No trial of semaglutide or tirzepatide has measured buttock shape or the gluteal muscles. What the trials do measure is the whole body: on tirzepatide, fat accounted for roughly 75% of the kilograms that came off and lean tissue for roughly 25%, and placebo showed the same split.^[3] Resistance training is the one intervention with randomized evidence for keeping more muscle. Surgery is the only treatment shown to remove loose skin.

Three tissues, three different clocks

Plastic surgeons who reshape the buttocks after massive weight loss describe three complaints: skin that sags, pockets of leftover fat, and lost projection, which is the flat look.^[13] Each maps onto a tissue that responds to weight loss in its own way and on its own timescale. Fat goes first and fastest. Muscle goes in proportion to the weight lost. Skin remodels slowly and only partly.

Fat: where the trials looked, and where they did not

The cleanest body-composition data on a GLP-1-based drug come from 160 people in SURMOUNT-1, nearly three quarters of them women, scanned by DXA before starting and again at week 72. The tirzepatide group ended 21.3% lighter, with 33.9% less fat mass and 10.9% less lean mass. On placebo the same three figures were 5.3%, 8.2% and 2.6%.^[3] Both obesity labels state the result in one line:

“Tirzepatide lowers body weight with greater fat mass loss than lean mass loss.”^[1]

— Zepbound prescribing information, section 12.2 (DailyMed)

The Wegovy label carries the same sentence for semaglutide.^[2] What the SURMOUNT-1 substudy did not do is break fat down by region below the waist. Its only regional output was an estimate of visceral fat taken from the lower trunk.^[3] The buttocks were inside the scan and outside the analysis.

The nearest thing to a buttock measurement on one of these drugs is older and smaller. In a 24-week randomized trial of 85 adults with type 2 diabetes and fatty liver, liraglutide reduced fat in every DXA region reported, including the trunk, the limbs and the gynoid region, the band across the hips and upper thighs.^[8] So the hip-and-buttock fat depot does respond. That trial used liraglutide at diabetes doses, not semaglutide or tirzepatide at obesity doses.

Why women may notice it more

A 12-week diet study scanned 88 adults by region. Women lost more fat from the legs than men did, 2.1 kg against 1.7 kg, while men lost more from the trunk, 5.0 kg against 3.9 kg.^[9] That was a calorie deficit, not a drug. It fits what most people see in the mirror: women carry more fat on the hips and thighs to begin with, so more of what they lose comes from there. Applying it to GLP-1 users is inference. No GLP-1 trial has reported the split by sex and region.

Cellulite on the buttocks and thighs does not move in one direction. In women tracked through supervised weight loss, most saw it improve. Some saw it worsen, and those were the ones who started at a lower body mass index, lost less weight, showed no drop in the share of fat on the thigh, and whose tissue became more compliant, meaning softer and looser.^[10]

Muscle: the part that gives the shape

Projection, the curve seen from the side, comes largely from the gluteal muscles under the fat. They are lean tissue, and lean tissue falls when weight falls. The question is how much.

A 2026 meta-analysis of 20 randomized trials and 15,782 people put the lean share of weight lost at 25.4% for tirzepatide and 35.2% for semaglutide. Diet and lifestyle programs without a drug came in at 26.2%, and the difference from the drugs was not significant.^[5] The full comparison is in lean mass on a drug versus dieting. A separate 2026 review of 35 studies found a median of 28.3% and noted that not one study measured physical function.^[6] Losing weight costs muscle by any route. These drugs make people lose a lot of weight.

The only GLP-1 imaging of lower-body muscle comes from STEP UP, a semaglutide trial in which 55 people had valid MRI scans. Against placebo, thigh muscle volume fell by about 1.1 liters, a difference that missed statistical significance (p = 0.07). Fat marbled inside the thigh muscle fell by 0.92 percentage points, which was significant. Chair stands in 30 seconds went from 13 at the start to 15 at week 72.^[7] The placebo group had six people, so those figures are imprecise. And the thigh is not the buttock.

Skin: the slowest tissue to adjust

Skin that held a larger body for years has been remodeled by it. Biopsies taken from 20 people after massive weight loss showed fewer thick, organized collagen fibers and more thin, misaligned, loosely arranged ones than skin from people still living with severe obesity.^[11] That is the structural reason stretched skin does not snap back once the volume under it is gone. On the buttocks, gravity adds a fold under the cheek and a lower crease.

A 2026 review of 40 studies of skin on GLP-1 drugs reported localized fat loss in several body regions leading to redundant folds. It listed older age, a longer history of obesity, rapid weight loss, poor hydration and low protein intake as risk factors for worse skin outcomes.^[12] Most of what it gathered was case reports and observational data, so those are associations, not tested causes. No cream, device or supplement has been shown to tighten gluteal skin after large weight loss.

Is it the drug, or the weight loss?

The record points to the weight loss. In SURMOUNT-1 the fat-to-lean split was the same on tirzepatide as on placebo; the drug changed how much weight came off, not what it was made of.^[3] The lean share on the drugs matched dieting.^[5] Plastic surgeons were reshaping deflated buttocks long before these drugs existed, and in one series of 52 gluteal reshaping patients, about a third had lost their weight by dieting rather than surgery.^[13]

Speed is the variable a person on the drug can affect. In STEP 1, semaglutide 2.4 mg produced a 14.9% loss over 68 weeks against 2.4% on placebo.^[4] That is a bariatric-scale result over a year or so. Rapid loss is one of the risk factors the skin review names.^[12] Whether a slower dose escalation protects the buttocks has never been tested; it is a plausible trade, and the cost is less weight lost in the same time.

What resistance training does

Training is the one lever with randomized evidence behind it, though none of the trials below measured the gluteal muscles and none gave a GLP-1.

The gluteal muscles are trained by loaded hip extension, the movement in squats, lunges, deadlifts and hip thrusts. Choosing glute-focused lifts to protect buttock shape is a logical step from the whole-body data. No study has tested it as a way to prevent “Ozempic butt.” Training also matters for bone, where one trial found exercise held hip bone density that liraglutide alone did not: see bone density and exercise on a GLP-1. The trials paired training with adequate protein; our protein calculator works out a target. A physical therapist or trainer can set the program, particularly for anyone with joint or back problems.

Training does not fix loose skin. It adds volume underneath, which can improve projection. It cannot shorten an envelope that is already too large.

What surgery can do, and what it costs

The plastic surgery literature has graded post-weight-loss deformities for two decades. The Pittsburgh Rating Scale, built from photographs of over 300 women after bariatric weight loss, scores 10 body regions from 0 (normal) to 3 (most severe).^[14] Among 410 post-bariatric patients surveyed in 2023, the buttocks ranked behind the abdomen, lower back and upper arms as a site people wanted treated, and only 25.1% had had any contouring surgery.^[15]

• Lift. A lower body lift removes a belt of skin around the waist and raises the buttocks and outer thighs. In 323 cases over 10 years, one center reported complications in 42% of patients, mostly seroma, a fluid collection, in 35%.^[16]
• Lift with the patient’s own tissue. Skin and fat that would be discarded can be folded under the buttock to add projection. In 185 body lifts, adding this step did not raise the complication rate.^[17] In a series of 52 patients, the median sagging grade fell from 3 to 1 and satisfaction rose from 1.85 to 4.31 on a five-point scale.^[13]
• Fat grafting (the “BBL”). A 2017 survey of 692 surgeons covering 198,857 gluteal fat grafting cases counted 32 deaths from fat entering the lungs, and the task force concluded the procedure appeared to carry higher mortality than any other aesthetic operation. Injecting into the muscle raised the risk.^[18] After large weight loss there may also be little donor fat left to move.

Timing matters more than technique. Weight that changes after the operation undoes the result, and weight usually comes back after a GLP-1 is stopped. The evidence on when weight has stabilized enough is in when it is safe to have the skin removed, and our skin removal cost and insurance tool covers what insurers tend to require.